Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Babies, Beta-Blockers, Birthmarks, and Beams: Hemangioma Management and Laser Pearls
Description
The presentation focuses on the management of infantile hemangiomas, which are benign vascular growths occurring in about 5% of infants. The speaker, a pediatric dermatologist, highlights the importance of early recognition and treatment to prevent complications like ulceration or scarring. Propranolol is identified as the gold standard treatment, effective since its FDA approval in 2008, while dosing guidelines are emphasized, particularly regarding dietary considerations. The presentation reviews risk factors for hemangiomas, noting that location impacts treatment decisions, especially those on the head, neck, and spine. It discusses various treatment approaches, such as laser techniques and alternative medications, and stresses collaboration with pediatricians for timely referrals. The use of guidelines and assessments to identify high-risk hemangiomas is also discussed, advocating for proactive management. Additionally, the speaker shares personal cases that illustrate challenges and successes in treatment, all while underscoring the importance of individualized care and communication with families. The dialogue wraps up by acknowledging the evolving landscape of hemangioma treatment and the need to adapt to patients' changing needs over time.
View moreConclusions
- Infantile hemangiomas are the most common benign vascular tumors in infants, with a varied clinical presentation that requires careful evaluation for treatment.
- Timing of intervention is crucial, as treatment during the proliferative phase can prevent complications and long-term morbidity.
- Propranolol is the first-line treatment for problematic infantile hemangiomas, with dosages needing to be tailored for safety and effectiveness.
- Ulcerated hemangiomas require prompt treatment to avoid secondary infections and complications; management may include topical antibiotics and pulsed dye laser therapy.
- Early referral to pediatric dermatologists leads to better outcomes and less risk of serious complications for infants with hemangiomas.
- Segmental hemangiomas and those located on high-risk anatomical sites have a significant risk of complications, including vision impairment and disfigurement, warranting active management.
- Topical treatments like Timolol can be effective for smaller or less aggressive hemangiomas, providing an alternative for families hesitant about systemic medications.
- Invasive treatments, such as surgical excision, may be necessary for complicated cases, but should be approached with a thorough understanding of the potential outcomes and risks.
- Chang L, et al. Growth Characteristics of Infantile Hemangiomas: Implications for Management. Pediatrics. 2008;122(2)
- Krowchuk DP, Frieden IJ, Mancini AJ, et al. Clinical Practice Guideline for the Management of Infantile Hemangiomas. Pediatrics. 2019;143(1)
- Puttgen KB, et al. Limited utility of repeated vital sign monitoring during initiation of oral propranolol for complicated infantile hemangioma. J Am Acad Dermatol. 2020
- Horii K, et al. Prospective study of the frequency of hepatic hemangiomas in infants with multiple cutaneous infantile hemangiomas. Pediatr Dermatol. 2011
- Meyer-Mueller C, et al. Worsening ulceration of infantile hemangioma after initiation or escalation of propranolol. Pediatr Dermatol. 2022
- Muñoz-Garza F, et al. Efficacy and Safety of Topical Timolol for the Treatment of Infantile Hemangioma in the Early Proliferative Stage: A Randomized Clinical Trial. JAMA Dermatol. 2021
- Patel D, Doshi DH, Desia A. Short term stability of atenolol in oral liquid formulations. Int J Pharm Compound 1997; 1(6):437-439.
- Nahata MC, Pai VB. Pediatric Drug Formulations, 6th edition. Cincinnati, OH: Harvey Whitney Books Co, 2011
- Bayart C, et al. Versus Propranolol for Treatment of Infantile Hemangiomas During the Proliferative Phase: A Retrospective Noninferiority Study. Pediatr Dermatol 2017
- Knopfel N, et al. Timolol for the treatment of pyogenic granuloma (PG) in children. J Am Acad Dermatol. 2016
- Skaljic M, et al. Comfort positioning during procedures in pediatric dermatology. Pediatr Dermatol. 2020
- Lyon V, et al. Toddler wrap for abdominal biopsy or excision. Pediatr Dermatol. 2008
- Sabeti S, et al. Consensus Statement for the Management and Treatment of Port-Wine Birthmarks in Sturge-Weber Syndrome. JAMA Dermatol. 2021
- Jeon H, et al. Pulsed Dye Laser Treatment of Port-Wine Stains in Infancy Without the Need for General Anesthesia. JAMA Dermatol. 2019